IMVT News and Press, Immunovant Inc.

2026-03-17 20:54:19 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 02/17/2026. The 13F portfolio value increased from $...

2026-03-15 15:59:36 ET On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant (NASDAQ:IMVT) , an estimated $24.53 million trade based on quarterly average pricing. According to a S...

2026-03-11 13:08:23 ET On February 17, 2026, Alpine Global Management disclosed a sale of 127,039 shares of Immunovant (NASDAQ:IMVT) , with an estimated transaction value of $2.83 million based on quarterly average pricing. According to a filing with the Securities and Exchang...

2026-02-06 13:24:18 ET Immunovant, Inc. (IMVT) Q3 2026 Earnings Call February 6, 2026 8:00 AM EST Company Participants Benjamin Zimmer - President of Health Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roiva...

2026-02-06 11:20:17 ET Image source: The Motley Fool. Tuesday, November 11, 2025 at 8:00 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-06 07:03:08 ET More on Immunovant Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement Immunovant, Inc. (IMVT) Q2 2025 Earnings Call Transcript Immunovant drops 7%, prices $550M stock offering Seeking Alpha’s Quant Ra...

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of ca...

Biogen Inc. (BIIB) is expected to report $1.6 for Q4 2025 Frontier Group Holdings Inc. (ULCC) is expected to report $0.02 for Q4 2025 Johnson Outdoors Inc. (JOUT) is expected to report $-0.45 for Q1 2026 Piper Sandler Companies (PIPR) is expected to report $4.72 for Q4 2025 Ispire...

2026-01-30 15:00:52 ET More on the markets 2026: The Year Of The Small Cap? U.S. Trade Deficit Stabilizes As Post-Tariff 'Front-Loading' Fades Evolution, Not Revolution For The Federal Reserve The Mag 7 are no longer trading as a unified group – T. Row...

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (Nasda...